Patent · US Active

Anti-HER3 antibody-drug conjugate

US10383878B2 · kind B2 · utility

26Cited by

10References

17Claims

0Family size

Assignees

DAIICHI SANKYO COMPANY, LIMITED · JP
DAIICHI SANKYO EUROPE GMBH · DE

Inventors

Thore Hettmann · Birkenfeld, DE
Reimar Abraham · Munich, DE
Sabine BLUM · Munich, DE
Suguru UENO · Tokyo, JP

Key dates

Filing date	Oct 4, 2016
Grant date	Aug 20, 2019
Priority date	—
Expiry date	Oct 4, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/77
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(═O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(═O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.